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Abstract
Introduction HER2 overexpression, or rather HER2  gene
amplification, is indicative for Herceptin therapy in both
metastatic and pre-metastatic breast cancer patients. Patient's
individual sensitivity to Herceptin treatment, however, varies
enormously and spans from effectual responsiveness over
acquired insensitivity to complete resistance from the outset.
Thus no predictive information can be deduced from HER2
determination so that molecular biomarkers indicative for
Herceptin sensitivity or resistance need to be identified. Both
ErbB receptor-dependent signalling molecules as well as
HER2-related ErbB receptor tyrosine kinases, known to mutually
interact and to cross-regulate each other are prime candidates
to be involved in cellular susceptibility to Herceptin.
Methods Using immunohistochemistry and fluorescence in situ
hybridisation, we retrospectively investigated primary breast
cancer tissues from 48 patients who were under Herceptin
treatment. We quantified the gene copy numbers of all HER
receptors and evaluated their coexpression profile. Moreover
the HER2 phosphorylation state, the ratio of native to truncated
HER2, p27(kip1) and PTEN expression were objects of this
study.
Results Above all markers investigated in this study Kaplan-
Meier and Cox regression analysis revealed a significant positive
impact of HER4 (co-)expression on overall survival from
beginning of antibody therapy. Both HER4 expression and
HER4 gene amplification emerged as independent prognostic
markers in Herceptin-treated breast cancer patients and
responsiveness to Herceptin turned out to be more efficient if
tumour cells show HER4 expression.
Conclusions Although HER4 is known to potentially exert a
tumour cell killing activity and in turn to have a favourable impact
in breast cancer patients we demonstrate here the first time that
HER4 expression prolongs overall survival in Herceptin-treated
patients. Elucidating HER4 receptor function in the context of
Herceptin treatment will advance the design of highly efficient
receptor targeting. By then we need to extend the analysis of
breast cancer by allowing for HER2/HER4 coexpression by
which valuable additional prognostic and predictive information
might possibly be revealed.
Introduction
The overexpressed human epidermal growth factor receptor
(HER) 2 receptor tyrosine kinase (RTK) is a useful therapeutic
target in breast cancer patients. In pathological diagnostics,
the HER2 expression level is routinely evaluated and an ele-
vated receptor expression (scored 3+) is usually based on
HER2 gene amplification, which can reliably be identified by in
situ hybridisation [1]. Without contraindication HER2 protein
overexpression (or HER2 gene amplification) represents the
worldwide accepted rationale for antibody-targeted therapy
using trastuzumab (Herceptin™). Herceptin™ was approved in
Europe in 2000 for the treatment of breast cancer patients suf-
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fering from metastatic and aggressive tumour growth that is
indicative for a poor disease outcome [2]. In fall 2006, Hercep-
tin™ treatment was extended by the approval for adjuvant
patient treatment [3]. Statistically considered, antigen-specific
targeting of tumour cells has brought significant clinical benefit
to these patients, both in terms of overall survival (OS) and
recurrence free survival (RFS) documented in many clinical tri-
als [4,5]. Although HER2 overexpression or HER2 gene ampli-
fication is a prerequisite for therapeutic antibody treatment,
the extent of sensitivity to Herceptin™ therapy varies enor-
mously and ranges from excellent individual responsiveness
over acquired insensitivity to complete resistance from the out-
set [6-9]. Consequently, HER2 overexpression does not rep-
resent a reliable predictive marker for responsiveness to
Herceptin™.
Numerous molecular biomarkers implicated in individual sensi-
tivity to Herceptin™ treatment have been suggested, but have
not been precisely and reproducibly defined to date. The panel
of suggested molecules comprises proteins involved in intrac-
ellular survival signalling (PTEN) [10] and cell proliferation
(p21, p27) [11-15], as well as cell membrane located mole-
cules featuring the capacity to directly interact with HER2 and
thereby modulate lateral and transversal HER2 activity [16].
Among them the HER2-related RTK family members HER1
(also known as epidermal growth factor receptor (EGFR)),
HER3 and HER4 are in the focus of interest [17]. Depending
on their coexpression profile HER receptors act in concert on
ligand binding and trigger transmembraneous signal transduc-
tion as a functional unit rather than individually and independ-
ently. The recruitment of intracellular signalling pathways is a
result of intensively cross-talking receptors and well-defined
three-dimensional intracellular activation domains [18]. Hence
a highly organised spatiotemporal coexpression of HER
receptors plays a pivotal role in growth, development and dif-
ferentiation both on the cellular and organ level in healthy
organisms [19,20]. However, HER1 and/or HER2 overexpres-
sion, as well as atypical HER receptor coexpression profiles,
causing receptor hyperactivation and enhanced mitogenic sig-
nalling, could have been frequently attributed to malignant cell
growth [17].
Moreover, HER3 has been found to preferentially interact with
HER2 [21] and, although kinase deficient, to significantly
enhance mitogenic signalling [22]. As a consequence even
antiproliferative effects mediated by Herceptin™ can be exten-
uated by HER3 coexpression [23]. Remarkably, receptor
coexpression does not necessarily result in hyperstimulation
and hypermitogenic cellular activity. Signal modulation, fine
tuning and control can also be achieved by extensive receptor
communication and even antiproliferative and induction of dif-
ferentiation responses on growth factor binding (i.e. heregulin)
to HER4 have been previously described [24,25].
Conceivably the tissue-specific coexpression of HER recep-
tors has immediate impact on the cellular response to Hercep-
tin™, which specifically binds to HER2. In a previous study we
have experimentally shown that the cellular sensitivity to Her-
ceptin™ treatment is directly contingent on the EGFR coex-
pression density and can be enhanced by EGFR
downregulation [26]. In another study undertaken in our labo-
ratory, we have shown that amplified HER3 and HER4 gene
copy numbers have additional prognostic impact on the
course of breast cancer disease in patients both with and with-
out HER2 gene amplification [27].
Here, in a series of 48 breast cancer patients with HER2 gene
amplification we retrospectively investigated numerous addi-
tional biomolecular parameters to have potential impact on the
course of disease under Herceptin™ treatment (prognostic
value) and to be implicated in responsiveness to Herceptin™
treatment (predictive value). Therefore, we quantified the gene
copy numbers of all HER  receptors via fluorescent in situ
hybridisation (FISH) and immunohistochemically investigated
the coexpression profile of all HER receptors. In addition, the
HER2 phosphorylation state, the ratio of native to truncated
HER2, the expression of p27kip1 and PTEN, and the presence
of the proliferation associated antigen Ki-67 were studied. As
inhibition of activated HER2 might be primarily responsible for
Herceptin™ sensitivity rather than the total receptor targeting
[28], we evaluated the pY1248 phosphorylation, which has
been linked to the mitogenic ras/MAP kinase signalling path-
way [29]. Herceptin™ is targeted to the juxtamembrane
domain of HER2 [30], so the loss of binding site by receptor
truncation could be suggestive for antibody resistance [31].
Furthermore, the identification of proteolytically shed HER2
(sHER2/p95) in relation to total HER2 expression could be
informative in terms of receptor activation and consequently
the efficacy of Herceptin™ binding. Moreover PTEN, a nega-
tive regulator of PKB/Akt, and p27kip1 both downstream tar-
gets of HER2, have been proposed to be involved in
Herceptin™ resistance [10,32].
The aim of this study was to cytogenetically and immunohisto-
chemically identify molecular biomarkers within the context of
HER receptor signalling, which affects the susceptibility of
metastatic breast cancer to Herceptin™ treatment. Of all the
markers investigated in this study, the presence of truncated
and phosphorylated receptors appeared to have an impact by
trend on the course of disease of Herceptin™-treated (HT)
patients. All Kaplan-Meier and Cox regression analyses
revealed a significant positive impact of HER4 (co-)expression
on OS from the beginning of antibody therapy. Finally both
HER4 expression and HER4 gene amplification emerged as
independent prognostic markers in HT breast cancer patients.
HER4 receptor expression is even supposed to provide pre-
dictive value because it apparently affects susceptibility to
Herceptin™ treatment.Available online http://breast-cancer-research.com/content/11/4/R50
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Materials and methods
This study was approved by the Institutional Review Board of
the University of Regensburg, Germany.
Breast tumour samples and patient characteristics
Formalin-fixed paraffin-embedded tissue blocks from 48
female patients with invasive lobular or ductal unilateral pri-
mary breast cancer (median age, 56.0 years; range 31.4 to
80.9) were obtained from the archives of the Institute of
Pathology, Regensburg, and the Institute of Pathology, Hospi-
tal Weiden, Germany. All patients were diagnosed between
March 1997 and October 2005 and underwent Herceptin™
therapy between September 2000 and November 2005. The
patients were not involved in any clinical trial. Clinical data
were acquired by the Tumour Centre Inc., Regensburg. The
median follow-up period was 55.8 months (range 28.4 to
116.6). The median OS time was 41.7 months (range 10.6 to
116.6), median RFS was 21.9 months (range 1.5 to 63.6). A
total of 36 patients (75%) died and 12 patients survived until
the end of monitoring. Of the 48 patients, 31 (65%) suffered
from a recurrence of breast cancer including the subgroups of
4 of the 12 surviving patients (33.3%) plus 27 of the 36 (75%)
patients who passed away.
Fluorescence in situ hybridisation
Tissue microarrays (TMAs) were constructed and handled as
described previously [27]. Briefly, after dewaxing and rehy-
drating, slides were steamed in sodium citrate. Cell structures
were digested in pepsin and hydrochloric acid, then washed
and dehydrated.
For FISH analyses, 5 μm sections of the TMAs directly labelled
dual-colour DNA probes for HER1 (7p11.2), HER2 (17q21-
22),  HER3  (12q13.2),  HER4  (2q33.3-34), and oestrogen
receptor α (ERα, 6q25) (ZytoVision Ltd., Bremerhaven, Ger-
many) were used. The probes identified locus-specific
sequences for both the genes and the corresponding centro-
meres 7, 17, 12, 2, and 6 to differentiate between gene ampli-
fication and polysomy of the respective chromosome.
Respective DNA probe sets were applied to the TMA area and
incubated overnight at 37°C. Subsequent to several washing
steps, nuclei were counterstained with DAPI (4',6-diamidino-
2-phenylindole) and analysed by epifluorescence microscopy.
FISH scoring was performed by counting fluorescence signals
in 25 malignant, non-overlapping cell nuclei for each case by
two independent interpreters (AS, MB). The FISH ratio was
assessed as the number of genes proportional to the number
of centromeres. Patients with HER2 ratios, that is total gene/
total centromere relations, of 1.5 or more were considered as
amplified based on recent statistical approaches of our group
[27] and included in this study.
TMA sections stained with H&E were used for reference his-
tology.
Microscopy, fluorescence in situ hybridisation scoring 
and digital imaging
Slides were imaged as described previously [27] with an Axio
Imager Z.1 (Zeiss, Göttingen, Germany), equipped with spe-
cific filter sets (AHF, Tübingen, Germany) and the plug-in mod-
ule ApoTome™ for taking pseudoconfocal images. Three-
dimensional z-stacks were generated, colours were separately
recorded and digitally processed. Corresponding images
were superimposed.
Immunohistochemistry
Immunostaining with anti-HER-receptor antibodies, anti-
phosphoHER2, anti-extracellular HER2, anti-ER, anti-proges-
terone receptor (PR), anti-p27kip1, and anti-PTEN was per-
formed on 5 μm sections of the TMAs and applied in
accordance with the manufacturer's instructions. Table 1
explicitly shows the antibody-specific staining and scoring
characteristics. Interpretation was performed independently
by two experienced pathologists (SS, FH). Stably transfected
mouse fibroblasts proved specific immunostaining of HER1 to
HER4 [27].
Anti HER1 to 4 and anti-Ki67 antibodies were assessed as
described previously [27]. HER2 phosphorylation status was
scored as suggested in the Herceptest™ guidelines. The clas-
sification into p27Kip1 positive (n = 24) and negative cases (n
= 24) was performed using an immunoreactive score (IRS),
defined by the following formula: nuclear staining (0 to 100%)
× intensity of staining (0 = no staining, 1 = weak staining, 2 =
moderate staining, 3 = strong staining) plus percentage of
cells with cytoplasmic staining × medial staining intensity. An
IRS of at least 200 was regarded as positive. Anti-PTEN stain-
ing (Rabbit monoclonal antibody, clone 138G6, Cell Signal-
ing, Boston, MA, USA) detected endogeneous levels of total
protein analogously to the above mentioned procedure con-
sidering nuclear and cytoplasmic staining, respectively. ER
and PR scoring was performed according to Remmele and
Stegner [33]. Anything but IRS 0 was considered positive.
Statistical analyses
The primary outcome measure, OS, was calculated as the time
from the beginning of Herceptin™ treatment to death from any
cause or to the date on which the patient was last known to be
alive. Patients lost to follow-up were treated as censored
cases on the basis of the last contact date. A secondary out-
come measure, RFS, was omitted because in our series Her-
ceptin™ treatment was primarily indicated after diagnosis of
relapse and/or in patients with metastatic breast cancer (M1,
R2) so that complete remission did not occur.
Survival curves were generated using the Kaplan-Meier
method, and log-rank tests compared the distributions
between groups. In addition, hazard ratios (HR) with 95% con-
fidence intervals (CI) were estimated for covariates (treated as
continuous, and where appropriate as a dichotomous variable)Breast Cancer Research    Vol 11 No 4    Sassen et al.
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using the Cox proportional-hazards model. Non-parametric
correlations were analysed by Spearman tests. In all analyses,
P ≤ 0.05 (two-tailed) was considered significant. Statistical
analyses were performed with SPSS version 16.0 (SPSS Inc.,
Chicago, IL, USA).
Results
Data validation
TMAs of paraffin-embedded samples from 48 HT breast can-
cer patients were used to analyse gene amplification and pro-
tein expression of each member of the HER family. Metastasis
as a prerequisite for patients receiving Herceptin™ therapy is
referred to as stage IV (defined as Tx, Nx, M1). We found one
grade 1 tumour (not included in the statistics), but 11 graded
2 (according to [34]) and 35 graded 3 with a trend for longer
survival with tumours graded 2 (P = 0.116, Figure 1). For OS,
patients age at various dichotomisations (cut-off points at 45,
50, 55 and 60 years) played no significant role (< 50 years, n
= 20 vs. ≥ 50 years, n = 28; P = 0.399).
Univariate Cox analysis (Table 2) revealed HER4 (FISH and
immunohistochemistry analysed), phosphoHER2 and p27Kip1
(immunohistochemistry) all to have a positive prognostic
impact on OS. A multivariate Cox analysis (backstep: LR) was
accomplished enclosing all parameters including HER1, 3, 4,
and ERα, FISH, HER1, 3, 4 immunohistochemistry, Ki67
immunohistochemistry, ER and PR immunohistochemistry,
grading, and age. The final step is shown in Table 3.
Fluorescence in situ hybridisation
HER1, HER3, HER4, and ERα were processed as continuous
variables instead of dichotomising the data due to indefinable
cut-off points [27]. HER1, HER3, and ERα FISH provided no
further information whereas HER4 gene amplification was a
significant positive marker for OS under Herceptin™ treatment
Table 1
Characteristics for immunostaining and scoring
Protein HER2 EC phospho-HER2 
(pY1248)
p27Kip1 Oestrogen receptor α Progesterone 
receptor
Antibody Rabbit mAb Mouse mAb Mouse mAb Mouse mAb Mouse mAb
Origin Thermo Scientific Thermo Scientific Lab Vision Novocastra Novocastra
Clone SP3 PN2A, Ab-18 DCS-72.F6, Ab-1 6F11 1A6
Dilution of primary 
antibody
1:50 1:100 1:100 1:60 1:40
Staining pattern Membrane Nucleus and 
cytoplasm
Nucleus
Epitope retrieval Heat induced, 10 mM citric acid buffer, pH 7.3 Heat induced, 10 mM 
sodium-citric acid pH 
6.0
Heat induced, 10 mM citric acid buffer, pH 7.3
Blocking Endogenous peroxidase blocking
Primary antibody 30 min, room 
temperature
Overnight, 4°C 30 min, room 
temperature
60 min, room 
temperature
Detection system EnVision™ Dual Link System; DAB + chromogenic substrate iVIEW™ DAB 
Detection Kit
Scoring in 
accordance with
HercepTest guidelines Immunoreactive score Manufacturer's guidelines
Anti-HER1 to 4 and anti-Ki-67 antibodies were applied as described previously [27].
EC = antibody binds to extracellular domain; HER = human epidermal growth factor receptor; mAb = monoclonal antibody.
Figure 1
Kaplan-Meier curve of tumour grading in Herceptin™-treated breast  cancer patients Kaplan-Meier curve of tumour grading in Herceptin™-treated breast 
cancer patients. P = 0.116.Available online http://breast-cancer-research.com/content/11/4/R50
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(HER4 continuous: HR = 0.003 (95% CI < 0.01 to 0.17), P =
0.005, Table 3) in multivariate cox analysis.
Immunohistochemistry of HER1, HER3, and HER4
All immunohistochemical results are shown in Table 4. Immu-
nostaining of all four HER receptors was performed. The spe-
cificity of applied antibodies was proved by staining stably
transfected mouse fibroblasts (NIH 3T3, kindly provided by
Roche Diagnostics, Penzberg, Germany, data shown else-
where [27]).
By immunohistochemistry, 22.9% (11 of 48) were identified as
HER1 positive (score 1+, 2+ and 3+) and 77.1% (37 of 48)
as negative. In 22.4% (48 of 214) HER2 was overexpressed
(score 2+ and 3+) and 77.6% (166 of 214) were unaltered.
Immunohistochemistry of HER3 resulted in 93% (39 of 47)
positive (score 1+, 2+ and 3+) and 17% (8 of 47) negative
patients. Of the total number of cases, 54.2% (26 of 48)
expressed HER4 (score 1+, 2+ and 3+), whereas 45.8% (22
of 48) did not.
As in the FISH results, HER1 and HER3 immunohistochemis-
try did not give further information (HER1 P = 0.278, HER3 P
= 0.982; Kaplan-Meier curves not shown). Remarkably, HER4
immunohistochemistry corroborates HER4  FISH findings.
HER4 expression resulted in significant longer survival times
of HT patients (P = 0.013; Figure 2).
Within the patient collective investigated in this study, besides
HER4 gene amplification and grading, HER4 immunohisto-
chemistry was found to have significant positive impact on OS
under Herceptin™ treatment (HR = 0.383 (95% CI 0.180 to
0.815), P = 0.013).
To evaluate Herceptin™ therapy, we matched the HT series (n
= 48) with a cluster of patients (n = 20) originating from a
recent study with no antibody-treated patients [27] and per-
formed Kaplan-Meier survival analyses. The criterion for
patient inclusion was their metastatic status (stage IV, M1
tumours).
Conventionally treated (CT) HER2-positive patients have the
shortest survival time. Herceptin™ therapy improves their OS,
but CT HER2-negative patients show the longest survival
times (Figure 3). Irrespective of CT HER2-positive patients, a
significant difference remains between HT HER2-positive
patients and CT HER2-negative patients (P = 0.037). Thus,
our statistical analysis is in agreement with the frequently
found observation that HER2 positivity is a negative prognos-
tic factor independent of therapy.
Considering therapy options (CT and HT), Herceptin™ clearly
ameliorated OS (Figure 4).
With given HER2 overexpression but independent of treat-
ment, HER4 positivity lengthened survival times. HER4 positiv-
ity showed a positive impact on OS both in CT and in HT
patients (curve 3 to 4, log rank, P = 0.013; and curve 1 to 2,
log rank, P = 0.083).
Comparing patients with HT and HER4 negativity and patients
with CT but HER4 positivity, no significant difference could be
found (log rank, P = 0.351).
Table 2
Univariate Cox proportional hazards analysis
Parameter Overall survival
HR 95% CI P
FISH HER1 0.45 0.12 to 1.787 0.256
HER3 1.14 0.34 to 37.51 0.943
HER4 <0.01 <0.01 to 0.33 0.011
ERα 1.19 0.71 to 2.00 0.511
IHC HER1 1.62 0.67 to 3.92 0.282
HER2 shedding 1.36 0.69 to 2.70 0.376
phospho-HER2 0.20 0.05 to 0.86 0.030
HER3 1.01 0.42 to 2.44 0.982
HER4 0.43 0.22 to 0.85 0.016
Ki-67 1.36 0.67 to 2.77 0.397
ER 1.00 0.92 to 1.08 0.979
PR 0.98 0.91 to 1.06 0.647
p27Kip1 0.42 0.21 to 0.84 0.014
Others Grading 2.01 0.83 to 4.87 0.123
Age (<50 vs. ≥ 50 years) 1.34 0.68 to 2.67 0.401
Overall survival was defined from beginning of Herceptin™ treatment. 
Hazard ratios (HR), confidence intervals (CI) and P values of 
investigated parameters dependent on overall survival. CI with lower 
and upper limits. Data in bold define significant results.
ER = oestrogen receptor; FISH = fluorescence in situ hybridisation; 
HER = human epidermal growth factor receptor; IHC = 
immunohistochemistry.
Table 3
Last step of multivariate Cox proportional hazards analysis
Parameter Overall survival
HR 95% CI P
HER4 IHC 0.38 0.18 to 0.82 0.013
HER4 FISH <0.01 <0.01 to 0.17 0.005
Grading 3.2 1.16 to 8.81 0.024
Overall survival was defined from beginning of Herceptin™ treatment, 
Cox analysis was performed stepwise backwards.
CI = confidence interval; HR = hazard ratio; FISH = fluorescence in 
situ hybridisation; HER = human epidermal growth factor receptor; 
IHC = immunohistochemistry.Breast Cancer Research    Vol 11 No 4    Sassen et al.
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Other immunohistochemical investigations
Regarding the HT patient series, p27Kip1 immunohistochemis-
try positive patients (n = 24) had a significantly better outcome
concerning OS compared with p27Kip1 negative (n = 24)
patients (Figure 5a, log rank, P = 0.012).
Phosphorylated HER2 receptor (Figure 5b) was associated
with increased OS (P = 0.016). In 16% of cases (7 of 43) we
documented a positive staining with a significant positive
effect on OS, whereas 84% of cases (36 of 43) showed less
or no staining.
To examine the proliferation status in our patient cohort we
assessed Ki-67 immunohistochemistry. The proliferative index
had no significant impact on the OS of patients (data not
shown).
All tumours were stained with two anti-HER2 antibodies. The
routinely used antibody binds an intracellular target and
showed a positive staining as expected in a HT patients series.
We compared the staining intensity and pattern with staining
obtained by using the SP3 antibody which targets a protrud-
ing extracellular HER2 domain (Table 4). In 22 cases we found
differences; in 20 cases the extracellular staining was weaker
than the intracellular, pointing out a shedding of the extracellu-
lar receptor domain. Comparing survival times of these 20
patients with those with homogeneous staining (n = 24), the
latter demonstrated a trend for decreased RFS times (P =
0.096).
Immunohistochemical staining of ER and PR did not yield any
supplemental information (ER P = 0.631, PR P = 0.593). The
Table 4
Results of immunohistochemical stainings
Scoring HER1 (n = 48) HER3 (n = 47) HER4 (n = 48) phospho-HER2 (n = 43) p27Kip1 (n = 48) ERα (n = 45) PR (n = 46)
0 37 (77.1) 8 (16.7) 22 (45.8) 36 (83.7) n/a n/a n/a
1 7 (14.6) 31 (64.6) 7 (14.6) 3 (7.0) n/a n/a n/a
2 3 (6.2) 8 (16.7) 12 (25.0) 4 (9.3) n/a n/a n/a
3 1 (2.1) 0 7 (14.6) 0 n/a n/a n/a
Negative 37 (77.1) 8 (16.7) 22 (45.8) 36 (83.7) 24 (50.0) 19 (42.2) 29 (63.0)
Positive 11 (22.9) 39 (81.2) 26 (54.2) 7 (16.3) 24 (50.0) 26 (57.8) 17 (37.0)
All 48 patients were HER2 FISH positive (ratio > 1.5). Numbers in parentheses are percentages. Results in bold define data considered positive 
for immunohistochemistry. n/a = not applicable, scoring defined in methodical chapter.
ER = oestrogen receptor; HER = human epidermal growth factor receptor; PR = Progesterone receptor.
Figure 2
Kaplan-Meier curve of dichotomised HER4 IHC in Herceptin™-treated  breast cancer patients Kaplan-Meier curve of dichotomised HER4 IHC in Herceptin™-treated 
breast cancer patients. P = 0.013. HER4 negative = score 0; HER4 
positive = score 1 to 3. HER = human epidermal growth factor recep-
tor; IHC = immunohistochemistry.
Figure 3
Kaplan-Meier curve of matched patient series Kaplan-Meier curve of matched patient series. P = 0.008. Herceptin™ 
therapy (n = 48) compared with conventionally treated HER2 positive 
(n = 4) and conventionally treated HER2 negative (n = 16) patients. CT 
= conventional therapy; HER = human epidermal growth factor recep-
tor; HT = Herceptin™ therapy.Available online http://breast-cancer-research.com/content/11/4/R50
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anti-PTEN antibody did not reveal any interpretable results and
was eliminated from evaluation.
HER2 and ER immunohistochemistry were negatively corre-
lated (P = 0.011, correlation coefficient = -0.374).
Discussion
Screening of HER2 aberration (both on a protein or DNA level)
as a prerequisite for Herceptin™ therapy does not allow the
courses of disease or individual therapy responses to be pre-
dicted, so numerous biomarkers with potential impact on Her-
ceptin™ responsiveness have moved into the focus of interest.
Utilising immunohistochemistry and FISH, we retrospectively
investigated the most likely parameters with immediate impact
on HER2 activity and Herceptin™ responsiveness in a cohort
of 48 HT breast cancer patients with HER2 amplification.
Here, we present first-hand data comprising expression of all
HER receptors as well as p27Kip1 receptor phosphorylation
and native vs. truncated HER2 staining.
Our study demonstrates for the first time that HER4 expres-
sion improves the outcome in a sub-collective of HER2-posi-
tive, HT breast cancer patients. First evidence indicating that,
irrespective of therapy, HER4 coexpression has a positive
impact on the outcome of breast cancer patients was pub-
lished in 2003 [35], indicating a potential anti-tumourigenic
effect mediated by the fourth member of the HER receptor
family discovered in 1993 [25]. From there on a significant
reduction of the proliferation indices in HER4-positive invasive
breast carcinomas was reported, suggesting HER4 itself has
a functional anti-proliferative or even protective capacity [36].
An association of HER4 expression and a favourable outcome
in breast cancer patients has independently been described
by Suo and colleagues [37] who found that HER4 coexpres-
sion obviously antagonises the effect of HER2 (over-)expres-
sion on the course of breast cancer disease.
Our observation that HER4 coexpression apparently favours
the outcome of HER2-positive, HT breast cancer patients indi-
cates that HER4 coexpression favours the HER2 targeting
with Herceptin™. This suggests a non-autonomous role of
HER4 but rather some degree of HER4/HER2 interplay what
Figure 4
Kaplan-Meier curve of matched patient series with HER2 overexpres- sion Kaplan-Meier curve of matched patient series with HER2 overexpres-
sion. P < 0.001. Herceptin™ therapy compared with conventionally 
treated HER2-negative patients as well as HER4 normal and overex-
pression. CT = conventional therapy; HER = human epidermal growth 
factor receptor; HT = Herceptin™ therapy.
Figure 5
Kaplan-Meier curve of p27Kip1 and HER2pY1248 in Herceptin™-treated breast cancer patients Kaplan-Meier curve of p27Kip1 and HER2pY1248 in Herceptin™-treated breast cancer patients. (a) Dichotomised p27Kip1 immunohistochemistry (P = 
0.012) and (b) phosphorylated HER2 receptor immunohistochemistry (P = 0.016). HER = human epidermal growth factor receptor.Breast Cancer Research    Vol 11 No 4    Sassen et al.
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is in agreement with data provided by Sartor and colleagues
[38]. They transfected HER2-positive cancer cells to overex-
press HER4, achieving a reduction in proliferation and an
increase in apoptosis which is suggestive of HER4 slowing
down HER2 signalling activity. Moreover, a differentiation
inducing effect by heregulin treatment in HER4 expressing
SUM44 and SUM102 breast cancer cells has been experi-
mentally demonstrated. This observation appeared to be inde-
pendent of HER2 expression, because HER2 elimination
could not eradicate the HER4 dependent decrease in cell
growth. However, we previously found the coexpressed EGFR
to contribute to cell susceptibility to Herceptin™ (and pertuzu-
mab) and thereby provided evidence for EGFR/HER2 interac-
tion playing a pivotal role in anti-HER2 targeting [26] in which
HER4 is also most likely to be involved in.
Although HER4 expression has been frequently attributed to
low-grade tumours with low proliferation activity [39], the dis-
cussion on the impact of HER4 on breast cancer progression
and outcome of disease appeared contradictory over the past
couple of years. This debate can be attributed to the ambiva-
lent function of HER4 representing either oncogenic or
tumour-suppressing activity [40]. Four differentially spliced
HER4 isoforms have been identified but never been distin-
guished in descriptive studies addressing HER4 expression in
primary cancer [41]. The JM-a/CYT-1 and JM-a/CYT-2 iso-
forms can be proteolytically cleaved by tumour necrosis factor-
α converting enzyme [40,42] and subsequently by γ-secretase
[43], whereas JM-b/CYT-1 and JM-b/CYT-2 variants repre-
sent non-cleavable counterparts [44] characterised by ligand-
independent activity that promotes cancer cell growth [43].
Commonly, only JM-a/CYT-1 and JM-a/CYT-2 variants are
expressed in tumour tissues at the same time [45]. The intrac-
ellular CYT isoforms differ by having (CYT-1) or not having
(CYT-2) a cytoplasmic binding site for phosphoinositide 3-
kinase. Upon cleavage of JM-a isoforms these intracellular
released HER4 domains (4ICD) can be differentially translo-
cated into intracellular compartments and, if cytoplasmically
located, subsequently trigger anti-proliferative and pro-apop-
totic signals [46,47]. In contrast, if translocated into the
nucleus, they have the capacity to trigger pro-proliferative and
survival promoting signalling [48-51] and accordingly a
nuclear localisation of 4ICD has been associated to shortened
survival of breast cancer patients [45]. In contrast, a mitochon-
drial accumulation of 4ICD, which evidently shares structural
and functional homology with BH3-only pro-apoptotic BCL-2
family members, has also been reported [46]. This in turn
results in a disturbance of mitochondrial membrane integrity.
This process typically entails an apoptotic cell death charac-
terised by mitochondrial permeabilisation, cytochrome-c efflux
and caspase activation, and can explain the protective role of
HER4.
The positive impact of HER4 on a patient's course of disease
as shown in this study is not only suggestive of its differentia-
tion promoting and potentially pro-apoptotic function but
rather for a Herceptin™ augmenting effect. As HER2 is prima-
rily phosphorylated on Herceptin™ treatment, as we have pre-
viously shown [52,16], it might be conceivable that HER4 can
be crossactivated and a subsequent release of 4ICD might
possibly enhance Herceptin™/HER2 triggered signalling.
HER4, if coexpressed to HER2, could synergistically extenu-
ate proliferative and survival signalling, for example via down-
regulation of ERK1/2 and PKB/Akt activity, respectively [53].
Numerous observations suggest that irrespective of any ther-
apeutic treatment HER4 expression is associated with
reduced tumour breast cancer aggressiveness, which is indic-
ative of its prognostic impact [27,35-39,51,54]. Moreover,
based on Kaplan-Meier analysis as illustrated in Figure 4, we
here provide evidence that the outcome of HER2/HER4 dou-
ble-positive patients is significantly better both under CT and
HT compared with those patients who were HER2-positive
but HER4 negative. The latter observation does not necessar-
ily designate a predictive value of HER4 but is indicative of the
positive effect of HER4 among patients characterised by a
well defined therapeutic setting (either CT or HT treatment).
Nevertheless, the molecular signalling background responsi-
ble for the higher efficiency of Herceptin™ treatment in HER2-
positive/HER4-positive patients versus HER2-positive/HER4-
negative patients needs to be experimentally elucidated in
detail and the experimental design should allow for investigat-
ing the predictive relevance of HER4 in consideration of its
oncogenic and tumour suppressing potential, respectively.
Deciphering the molecular effect of HER4, which enhances
therapy efficiency of Herceptin™ treatment, would affect the
decision to undergo Herceptin™-related therapy but the pres-
ence of HER4 could be potentially therapeutically addressed
in the future as well. It would not be advisable, for instance, to
use novel anti-HER2 drugs, which would eradicate the ther-
apy-enhancing effect of HER4. Alternatively one could con-
sider therapeutically eliciting or intensifying the Herceptin™
enhancing effect of HER4.
The induction of the cyclin-dependent kinase inhibitor p27Kip1
protein is considered as a key mechanism on anti-HER2 tar-
geting using Herceptin™ by which at least six signalling targets
and pathways might be modulated [12]. Also, in this study
HER2 overexpressing patients with upregulated p27Kip1, ben-
efit significantly from antibody therapy indicating a prognostic
value of this protein in HT patients, which is in agreement with
other reports [55,56].
Patients respond more efficiently to Herceptin™ treatment if
HER2-Tyr1248 [56] is phosphorylated suggesting that Her-
ceptin™ affects an activated rather than an inactive receptor.
However, other sites may influence the response to Hercep-
tin™ [57].
Even if no correlation between HER4 and ER status could be
found in our study, the signalling crosstalk of HER receptorsAvailable online http://breast-cancer-research.com/content/11/4/R50
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with the ERα needs to be functionally explored in more detail.
4ICD has been shown to potentially activate ERα and in turn
to stimulate tumour cell proliferation [51]. Accordingly, Tovey
and colleagues showed a significantly poorer survival in ER-
positive breast cancer patients by detecting nuclear HER4
localisation [58], highlighting the importance of 4ICD/ERα
interplay.
Current approaches in developing novel anti-HER receptor
targeted drugs that block the entire type 1 RTK family via 'pan-
HER' blockade [59] may be counterproductive due to the
ambivalent function of HER4. HER4 overexpression or ampli-
fication dependent on the prevalent isoform confers a reduced
risk [27,54]. Hence development of selective type 1 RTK
inhibitors leaving HER4 signalling unaffected may prove more
advantageous. On the contrary, antibodies selectively target-
ing HER4 JM-a, such as the recently introduced monoclonal
antibody 1479 [60], could have therapeutic potential, assum-
ing that JM-a-specific antibodies are expected not to cause
adverse effects in tissues, such as the heart, that exclusively
express ErbB4 JM-b.
Conclusions
Further studies addressed to elucidate HER4 receptor func-
tion in the context of Herceptin™ treatment are necessary to
guide the design of highly efficient therapeutic strategies
based on HER receptor targeting. Extending the data pre-
sented here by stratifying larger patient cohorts characterised
by their HER2/HER4 coexpression profile will disclose the
impact of HER4 on anti-HER2 targeted Herceptin™ treatment
compared with conventional therapy of HER2-positive breast
cancer patients. Potentially the evaluation of HER4 expres-
sion, by which valuable additional prognostic or even predic-
tive information might possibly be revealed either from
immunohistochemistry or FISH even without differentiating
between HER4 splice variants, could contribute to therapy
decisions and/or optimisation in the future.
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